Cantor Fitzgerald Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $152
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska maintains a Neutral rating on Sarepta Therapeutics (NASDAQ:SRPT) and lowers the price target from $167 to $152.
August 08, 2024 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cantor Fitzgerald analyst Kristen Kluska maintains a Neutral rating on Sarepta Therapeutics and lowers the price target from $167 to $152.
The lowered price target from $167 to $152 by Cantor Fitzgerald suggests a less optimistic outlook for Sarepta Therapeutics, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100